| Date | Title | Description |
| 26.07.2024 | Advancing Dermatological Research: The American Skin Association's 2024 Grants**
** | ** The American Skin Association (ASA) has taken a bold step forward in the fight against skin diseases. On July 22, 2024, the ASA announced its 2024 research grants, a lifeline for scientists dedicated to understanding and treating skin co... |
| 26.07.2024 | BioVaxys and American Skin Association: Pioneering Paths in Medical Research**
** | ** In the ever-evolving landscape of medical research, two organizations stand out: BioVaxys Technology Corp. and the American Skin Association (ASA). Each is carving a niche in their respective fields, focusing on innovative solutions for ... |
| 22.07.2024 | AMERICAN SKIN ASSOCIATION ANNOUNCES 2024 RESEARCH GRANTS FOR SKIN CANCER AND DISEASES | NEW YORK, July 22, 2024 /PRNewswire/ -- American Skin Association has announced the names of the three Investigative Scientist Awards. Andrew Ji, MD of Icahn School of Medicine at Mount Sinai was awarded the ASA Sanofi Investigative Scienti... |
| 10.03.2024 | Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting | Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 1
39.4% of children treated with roflumilast cream 0.05% achie... |
| 10.03.2024 | Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting | - |
| 09.03.2024 | New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction | Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signature
Suggests skin barrier disruption in seborrheic dermatitis is distinct with its own disease-specific pattern
SAN DIEGO, Calif., M... |
| 05.03.2024 | Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | - |
| 04.03.2024 | Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the c... |
| 21.11.2022 | Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report | Report highlights efforts to advance diversity and inclusion, access to medicine, sustainable business practices, and governance
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningfu... |
| 26.09.2022 | Arcutis' formulation of old AstraZeneca drug clears another PhIII test | Weeks after rolling out its first psoriasis treatment, Arcutis Biotherapeutics is racking up more positive Phase III data for a second formulation of an old AstraZeneca drug.
The Phase III ARRECTOR trial tested roflu... |
| 08.09.2022 | LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million | LONDON, UK, 08 September 2022 — LifeArc today announced that its portfolio company Ducentis BioTherapeutics, a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases, has been ... |
| 08.09.2022 | LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million | LONDON, UK, 08 September 2022 — LifeArc today announced that its portfolio company Ducentis BioTherapeutics, a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases, has been ... |
| 08.09.2022 | VC firm LifeArc sells first portfolio company as dermatitis-focused Ducentis bought by Arcutis for $30M | LifeArc Ventures’ billion-pound investment strategy appears to be paying off, as the British life sciences VC fund saw its first portfolio company sold off in the form of Ducentis BioTherapeutics.
LifeArc has been the biggest investor in Du... |
| 23.12.2021 | Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners | - |
| 23.12.2021 | Arcutis Biotherapeutics, Inc. Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners | Arcutis Biotherapeutics, Inc. announced that it has obtained a $225 million term loan facility from funds managed by SLR Capital Partners. This additional capital further strengthens Arcutis balance sheet in advance of a potential 2022 Foo... |
| 23.12.2021 | Arcutis Biotherapeutics : Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners - Form 8-K | Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners
WESTLAKE VILLAGE, Calif., Dec 23, 2021 - Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on d... |
| 23.12.2021 | Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners | WESTLAKE VILLAGE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it has... |
| 23.12.2021 | Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners | WESTLAKE VILLAGE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it has... |
| 04.11.2021 | Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update | Submitted New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis across the full spectrum of disease
Initiated single pivotal Phase 3 trial of roflumilast foam in scalp and body psoriasis
Enrolling pivotal Ph... |
| 04.11.2021 | Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update - Form 8-K | Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update
•Submitted New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis across the full spectrum of disease
•Initiated single pivo... |
| 05.08.2021 | Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update | Anticipates submission of a New Drug Application (NDA) for topical roflumilast cream as a potential treatment for plaque psoriasis late in the third quarter or early in the fourth quarter of 2021
Initiated single pivotal Phase 3 trial of to... |
| 07.12.2020 | Arcutis Biotherapeutics : Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Trea... | Phase 3 trials’ topline data anticipated in the first quarter of 2021 and potential New Drug Application (NDA) submission anticipated by the end of 2021Roflumilast cream potential “Best in Class” topical PDE4 inhibitorPlaque psoriasis affec... |
| 07.12.2020 | ARCUTIS BIOTHERAPEUTICS, INC.
Arcutis Biotherapeutics : Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumi... | Phase 3 trials’ topline data anticipated in the first quarter of 2021 and potential New Drug Application (NDA) submission anticipated by the end of 2021Roflumilast cream potential “Best in Class” topical PDE4 inhibitorPlaque psoriasis affec... |
| 16.09.2020 | ARCUTIS BIOTHERAPEUTICS, INC.
Arcutis Biotherapeutics : Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Tre... | Roflumilast cream potential “Best in Class” topical PDE4 inhibitor
Plaque psoriasis affects approximately 8.6 million patients in the U.S.
Phase 3 trials topline data now anticipated in the first quarter of 2021 and New Drug Application (ND... |
| 16.07.2020 | ARCUTIS BIOTHERAPEUTICS, INC.
Arcutis Biotherapeutics : The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis' ARQ-151 (Topical Roflumilast Cream) for the Trea... | Data demonstrate potential “Best in Class” topical PDE4 inhibitor roflumilast significantly improves chronic plaque psoriasis
Phase 3 topline data anticipated first half of 2021
WESTLAKE VILLAGE, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Ar... |
| 21.10.2019 | Arcutis Announces the Completion of $94.5 million Series C Financing | - |
